Expanding Laws, Limited Evidence: Involuntary Commitment for Substance Use Disorders

Involuntary civil commitment (ICC) for substance use disorders is framed as a public health response to overdoses and functional impairment, yet evidence of its effectiveness remains limited. Federal attention to this practice in July 2025 heightens the need for rigorous evaluation to inform policies and clinical care. As of December 2024, a total of 36 states and the District of Columbia authorized substance-related ICC, whereas 14 states limited commitment to other psychiatric diagnoses. State laws vary regarding eligibility, safeguards, and maximum duration, and many do not require less restrictive alternatives or specify evidence-based care. Beyond this heterogeneous legal landscape, no national estimates are available regarding how many people are subjected to ICC for substance use disorders, and outcome data remain scarce. Existing evidence provides little clarity on implementation, patient-centered outcomes, postdischarge recovery, or social and ethical consequences. ICC statutes intersect with emergency and inpatient psychiatry, and they directly affect how psychiatric services evaluate overdose or suicidality, assess less restrictive alternatives, and transition patients into evidence-based addiction care. This assessment outlines a multidisciplinary research agenda focused on epidemiology, quasi-experimental evaluation, implementation, patient-centered outcomes, cost-effectiveness, and ethics. Current evidence does not support broad use of ICC for substance use disorders, and encouraging this practice risks unintended harm.